Cat. No. 4776
Chemical Name: (5R)-5-[(4-Bromophenyl)methyl]-3-(3
Biological ActivityPotent negative allosteric modulator of LFA-1 (lymphocyte function-associated antigen-1) (Kd = 26 nM). Binds to the I-domain of LFA-1. Reversibly inhibits LFA-1 mediated binding of SKW3 leukemia cells to ICAM-1. Inhibits superantigen (SEB)-induced IL-2 production from lymphocytes in vitro and attenuates the SEB-induced increase in IL-2 plasma levels in a mouse model in vivo. Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Wu et al (2004) Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-alpha]imidazol-2-one derivatives. J.Med.Chem. 47 5356. PMID: 15481974 .
Last-Barney et al (2001) Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein--protein interaction. J.Am.Chem.Soc. 123 5643. PMID: 11403595.
Kelly et al (1999) Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J.Immunol. 163 5173. PMID: 10553036.
If you know of a relevant reference for BIRT 377 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BIRT 377 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BIRT 377, supplier, BIRT377, potent, negative, allosteric, modulators, LFA-1, lymphocyte, function-associated, antigen-1, cell, adhesion, orally, available, integrins, Tocris Bioscience, Integrin Modulator products
Find multiple products by catalog number
New Products in this Area
Toll-like receptor (TLR) 5/Flagellin complex antagonistBioymifi
DR5 (TRAIL receptor) agonist; induces apoptosisBOP
Dual α9β/1α4β1 integrin inhibitor; preferentially mobilizes HSCs
September 27 - 30, 2017